Histology-Agnostic Drugs: A Paradigm Shift-A Narrative Review.

ABSTRACT: Cancer diagnosis and therapeutics have been traditionally based on pathologic classification at the organ of origin. The availability of an unprecedented amount of clinical and biologic data provides a unique window of opportunity for the development of new drugs. What was once treated as a homogeneous disease with a one-size-fits-all approach was shown to be a rather heterogeneous condition, with multiple targetable mutations that can vary during the course of the disease. Clinical trial designs have had to adapt to the exponential growth of targetable mechanisms and new agents, with ensuing challenges that are closer to those experienced with rare diseases and orphan medicines. To face these problems, precision/enrichment and other novel trial designs have been developed, and the concept

SUBMITTER: Mansinho A 

PROVIDER: S-EPMC10070286 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature